Get the Stockscreener App
25.43
0.22%
-16.29
Flexion Therapeutics, Inc. stock is traded at $25.43, with a volume of 5,554.
It is down -0.22% in the last 24 hours and down -2.04% over the past month.
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee. The company also develops FX101 and FX201, which is a pre-clinical stage programs for the treatment OA of large joints. The company was founded in 2007 and is headquartered in Burlington, Massachusetts.
See More
Previous Close:
$9.14
Open:
$25.38
24h Volume:
5,554
Relative Volume:
66.00
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-13.53
EPS:
-1.88
Net Cash Flow:
-
1W Performance:
+0.00%
1M Performance:
-2.04%
6M Performance:
+10.95%
1Y Performance:
-15.87%
1-Day Range:
$25.32
$25.50
1-Week Range:
$25.32
$25.50
52-Week Range:
$25.32
$25.50
Flexion Therapeutics, Inc. Stock (FLXN) Company Profile
Name
Flexion Therapeutics, Inc.
Sector
Phone
781-305-7777
Address
10 Mall Road, Suite 301, Burlington
Compare FLXN vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FLXN
Flexion Therapeutics, Inc.
|
25.43 | 0 | 0 | 0 | 0 | 0.00 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.08 | 58.26B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.93 | 54.44B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.61 | 48.41B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.28 | 39.33B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
498.65 | 22.12B | 3.13B | 1.27B | 1.12B | 26.39 |
Flexion Therapeutics, Inc. Stock (FLXN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Aug-20-20 | Initiated | Goldman | Neutral |
| Jul-31-20 | Initiated | Oppenheimer | Outperform |
| Jul-29-20 | Initiated | Credit Suisse | Outperform |
| Jun-25-20 | Initiated | H.C. Wainwright | Buy |
| May-27-20 | Initiated | Guggenheim | Buy |
| Dec-27-19 | Reiterated | The Benchmark Company | Buy |
| Dec-05-19 | Initiated | Craig Hallum | Buy |
| Nov-25-19 | Initiated | BTIG Research | Buy |
| May-09-19 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-04-19 | Reiterated | Needham | Buy |
| Jan-04-19 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-28-18 | Initiated | The Benchmark Company | Buy |
| Oct-09-17 | Reiterated | Needham | Buy |
| Aug-24-17 | Initiated | Northland Capital | Outperform |
| Dec-22-16 | Initiated | Raymond James | Strong Buy |
| Sep-06-16 | Resumed | Lake Street | Buy |
| Jul-21-16 | Initiated | Lake Street | Buy |
| May-03-16 | Resumed | Wells Fargo | Outperform |
| Nov-04-15 | Initiated | Cantor Fitzgerald | Buy |
| Sep-09-15 | Reiterated | Needham | Buy |
View All
Flexion Therapeutics, Inc. Stock (FLXN) Latest News
Joint Pain Injections Market Overview and Leading Players: - openPR.com
PCRX Stock Down 10% as Preliminary Q4 Revenues Miss Estimates - Finviz
Flexion Therapeutics, Inc.Common Stock (NQ: FLXN - FinancialContent
Flexion Therapeutics Announces Publication of Analysis of Patients with Unilateral Knee OA from Pivotal Trial of ZILRETTA® (... - ADVFN
Flexion Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Updates - ADVFN
Flexion Therapeutics Announces Publication of Independent Data Review of ZILRETTA® (triamcinolone acetonide extended-release... - ADVFN
Flexion Therapeutics Announces Publication of Pooled Analysis of Phase 2/3 Data on Use of Rescue Medication with ZILRETTA® (... - ADVFN
Osteoarthritis Therapeutics Market Size to Hit USD 26.31 billion by 2035 - Precedence Research
Anti-Inflammatory Therapeutics Market Size to Hit USD 164.44 Bn by 2035 - Precedence Research
Knee Osteoarthritis Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - The Globe and Mail
Musculoskeletal Pain Treatment Market Size (7MM) is expected to grow at a significant CAGR by 2034, estimates DelveInsight - The Globe and Mail
PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer - pharmiweb.com
Musculoskeletal Pain Treatment Market Size in the 7MM is expected to grow by 2034, estimates DelveInsight - openPR.com
Osteoarthritis Gene Therapy Market Research Report 2025 - InsightAce Analytic
Knee Osteoarthritis Pipeline Drugs Insights Report 2025: Emerging Therapeutics and Market Opportunities Revealed | DelveInsight - The Globe and Mail
Knee Osteoarthritis Pipeline Drugs Insights Report 2025: - openPR.com
Swollen Knee Treatment Market Expands as Demand for Non-Invasive Therapies Accelerates Globally - newstrail.com
Cipher Mining Inc.Common Stock (NQ: CIFR - FinancialContent
Knee osteoarthritis Market: Epidemiology, Therapies, Companies, DelveInsight | Centrexion Therapeutics, Pfizer, Eli Lilly, Ampio Pharmaceuticals, Galapagos NV, Cytonics, Flexion Therapeutics - Barchart.com
Knee Osteoarthritis Pipeline Analysis 2025: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight - The Globe and Mail
Non-opioid pain drug maker Pacira lays off 71 in California, retires facility in manufacturing upgrade - Fierce Pharma
Non-Opioid Pain Treatment Market Size, Share | CAGR Of 8.1% - Market.us
High Costs of Knee Osteoarthritis Treatment - Market.us
Knee Osteoarthritis (OA) Injectable Treatments Market Revenue to Attain USD 5.94 Bn by 2033 - Precedence Research
Flexion Therapeutics (NASDAQ:FLXN) - intelligentinvestor.com.au
Syncromune Appoints Kerri-Ann Millar as Chief Financial Officer - citybiz
Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer - GlobeNewswire
Marquis Who's Who Honors Shomari Hogan, MD, for Expertise in Consulting Services - 24-7 Press Release Newswire
Osteoarthritis Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Epidemiology, Revenue, Statistics, Therapies, and Companies by DelveInsight - Barchart.com
Pacira BioSciences Reports Fourth Quarter and Full-Year 2024 Financial Results - GlobeNewswire
Osteoarthritis Therapeutics Market Size [2033] Report - SkyQuest
Osteoarthritis Therapeutics Market Size to Reach USD 24.34 Bn by 2034 - GlobeNewswire
From bench to bedside: Osteoarthritis gene therapy developed in the lab at Baylor is in clinical trials nationwide - Baylor College of Medicine Blog Network -
Gene Therapies For Rare Diseases Market Share, Size, Growth and Forecast to 2031 - Insightace Analytic
Global Non-Steroidal Anti-Inflammatory Drugs Market is - GlobeNewswire
Avalo Therapeutics Welcomes Chief Medical Officer - Contract Pharma
Madison Topic FLEXION THERAPEUTICS, INC. | News, Weather, Sports, Breaking News - WMSN
Osteoarthritis Injectables Market Size & Share Report, 2030 - Grand View Research
U.S. Osteoarthritis Injectables Market | Industry Report, 2030 - Grand View Research
Global Medical Dynamometers Market to Witness Upsurge in Growth at a CAGR of ~6% by 2030 | DelveInsight - PR Newswire
Apnimed Appoints John Yee, MD, MPH, as SVP, Medical Affairs - GlobeNewswire
Is Osteoarthritis Cure — ARPA-H NITRO — Rocket Fuel Or TNT? - Clinical Leader
Knee Osteoarthritis Market to Witness Upsurge in Growth, Assesses DelveInsight | Key Companies To Look OutTechfields, Centrexion, Biosplice, Ampio, Paradigm, Grünenthal, Naturecell, MiMedx, TissueTech, Organogenesis - Yahoo Finance
Joint Pain Injections Market Strategic Market Study 2033 - SkyQuest Technology Consulting
Ascidian Therapeutics Announces Three Key Development Team Appointments as It Advances Its Lead Program Toward the Clinic - PR Newswire
Global Joint Pain Injections Market Size & Share Revenue Is - GlobeNewswire
Osteoarthritis Therapeutics Market to Register a Steady CAGR of 8.70% Between 20222030 - Digital Journal
Versant Development Fund Iii, L.p. Net Worth (2025) - GuruFocus
Utpal Koppikar named Alphabet health firm Verily CFO - The American Bazaar
Indian American Utpal Koppikar Named CFO of Alphabet Precision Health Company Verily - American Kahani
Verily Appoints Utpal Koppikar as Chief Financial Officer - FinancialContent
Flexion Therapeutics, Inc. Stock (FLXN) Financials Data
There is no financial data for Flexion Therapeutics, Inc. (FLXN). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
8.08%
Cap:
|
Volume (24h):